Revive Therapeutics Announces Brokered Private Placement of up to $2 million

by rvvadmin | Feb 11, 2020 | 2020

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Feb. 11, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences...

Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing

by rvvadmin | Feb 10, 2020 | 2020

TORONTO, Feb. 10, 2020 – Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the...

Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

by rvvadmin | Feb 5, 2020 | 2020

TORONTO, Feb. 05, 2020 – Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units...

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

by rvvadmin | Jan 20, 2020 | 2020

TORONTO, Jan. 20, 2020 – Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s...

Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

by rvvadmin | Jan 6, 2020 | 2020

TORONTO, Jan. 06, 2020 – Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE: RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical...